New migraine drug shows promise in Real-World study
NCT ID NCT05709106
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how well the migraine medication Rimegepant works in real-world settings. Researchers followed 173 adults with migraines who took the drug as needed for acute attacks or long-term prevention. Participants recorded pain levels at several time points after dosing and tracked monthly migraine days to assess effectiveness and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine
Boao, Hainan, 571434, China